Search results
Results from the WOW.Com Content Network
Catecholaminergic means "related to catecholamines". The catecholamine neurotransmitters include dopamine , epinephrine (adrenaline), and norepinephrine (noradrenaline). A catecholaminergic agent (or drug ) is a chemical which functions to directly modulate the catecholamine systems in the body or brain.
Besides enhancing catecholaminergic activity, it has additionally been found to decrease serotonergic activity. [20] Selegiline's metabolite desmethylselegiline has also been found to be active as a CAE. [21] [22] Aside from selegiline and its metabolites, D-deprenyl is a CAE, with slightly lower potency than selegiline. [20]
Catechol. A catecholamine (/ ˌ k æ t ə ˈ k oʊ l ə m iː n /; abbreviated CA) is a monoamine neurotransmitter, an organic compound that has a catechol (benzene with two hydroxyl side groups next to each other) and a side-chain amine.
The mechanisms of sympathomimetic drugs can be direct-acting (direct interaction between drug and receptor), such as α-adrenergic agonists, β-adrenergic agonists, and dopaminergic agonists; or indirect-acting (interaction not between drug and receptor), such as MAOIs, COMT inhibitors, release stimulants, and reuptake inhibitors that increase the levels of endogenous catecholamines.
Ephedrine, one of the most well-known selective NRAs.. A norepinephrine releasing agent (NRA), also known as an adrenergic releasing agent, is a catecholaminergic type of drug that induces the release of norepinephrine (noradrenaline) and epinephrine (adrenaline) from the pre-synaptic neuron into the synapse.
6-Hydroxydopa (6-OH-DOPA; 6-OHDOPA) is a catecholaminergic neurotoxin that damages noradrenergic and dopaminergic neurons and is used in scientific research. [1] [2] [3] It is a precursor and prodrug of 6-hydroxydopamine (6-OHDA).
1-Phenyl-2-propylaminopentane (PPAP), also known as α,N-dipropylphenethylamine (DPPEA) and by the developmental code name MK-306, is an experimental drug related to selegiline which acts as a catecholaminergic activity enhancer (CAE).
The drug has been determined to be a catecholaminergic activity enhancer when present in minuscule concentrations far below those at which monoamine oxidase inhibitory activity can be observed, thereby potentiating the release of catecholamine neurotransmitters in response to stimuli.